Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma

Translational Research

Volumn 164, Issue 5, 2014, Pages 411-423

  Milosevic, Zorica ^a   Pesic, Milica ^a   Stankovic, Tijana ^a   Dinic, Jelena ^a   Milovanovic, Zorka ^b   Stojsic, Jelena ^c   Dzodic, Radan ^b,d   Tanic, Nikola ^a   Bankovic, Jasna ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; ALCOHOL DEHYDROGENASE; ANTINEOPLASTIC AGENT; LACTATE-MALATE TRANSHYDROGENASE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER PATIENT; CANCER PROGNOSIS; CHEMOSENSITIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; ONCOGENE; ONCOGENE N RAS; ONCOGENE RAS; P53 GENE; PROTEIN EXPRESSION; RARE DISEASE; SIGNAL TRANSDUCTION; THYROID CANCER CELL LINE; THYROID CARCINOMA; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALCOHOL OXIDOREDUCTASES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908250080     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.06.005     Document Type: Article

References (61)

1. S.N. Pinchot, R.S. Sippel, and H. Chen Multi-targeted approach in the treatment of thyroid cancer Ther Clin Risk Manag 4 2008 935 947
2. G.E. Galliano, and D.P. Frishberg Pathology and classification of thyroid tumors G.D. Braunstein, Thyroid cancer 2012 Springer US 1 33
3. A. Taccaliti, F. Silvetti, G. Palmonella, and M. Boscaro Anaplastic thyroid carcinoma Front Endocrinol (Lausanne) 3 2012 84
4. I. Sugitani, A. Miyauchi, K. Sugino, T. Okamoto, A. Yoshida, and S. Suzuki Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients World J Surg 36 2012 1247 1254
5. N. Besic, and B. Gazic Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution Thyroid 23 2013 709 713
6. G. Nagaiah, A. Hossain, C.J. Mooney, J. Parmentier, and S.C. Remick Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment J Oncol 2011 2011 542358
7. O. Derbel, S. Limem, and C. Segura-Ferlay Results of combined treatment of anaplastic thyroid carcinoma (ATC) BMC Cancer 11 2011 469
8. S.A. Hundahl, I.D. Fleming, A.M. Fremgen, and H.R. Menck A National Cancer Data Base Report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments] Cancer 83 1998 2638 2648
9. Y. Kitamura, K. Shimizu, and M. Nagahama Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases J Clin Endocrinol Metab 84 1999 4043 4049
10. Z. Liu, P. Hou, and M. Ji Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers J Clin Endocrinol Metab 93 2008 3106 3116
11. M.C. Mendoza, E.E. Er, and J. Blenis The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation Trends Biochem Sci 36 2011 320 328
12. J.A. McCubrey, L.S. Steelman, and S.L. Abrams Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 2006 249 279
13. H.M. Wang, Y.W. Huang, and J.S. Huang Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma Ann Surg Oncol 14 2007 3011 3018
14. R.M. Quiros, H.G. Ding, P. Gattuso, R.A. Prinz, and X. Xu Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations Cancer 103 2005 2261 2268
15. C. Nucera, M.A. Nehs, and S.S. Nagarkatti Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer Oncologist 16 2011 296 309
16. V.G. Antico Arciuch, M.A. Russo, and M. Dima Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors Oncotarget 2 2011 1109 1126
17. R.C. Smallridge, and J.A. Copland Anaplastic thyroid carcinoma: pathogenesis and emerging therapies Clin Oncol (R Coll Radiol) 22 2010 486 497
18. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
19. L.C. Cantley, and B.G. Neel New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc Natl Acad Sci U S A 96 1999 4240 4245
20. P.L. Dahia, D.J. Marsh, and Z. Zheng Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors Cancer Res 57 1997 4710 4713
21. P. Crespo, and J. Leon Ras proteins in the control of the cell cycle and cell differentiation Cell Mol Life Sci 57 2000 1613 1636
22. P. Rochefort, B. Caillou, and F.M. Michiels Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter Oncogene 12 1996 111 118
23. H.G. Suarez, J.A. du Villard, and M. Severino Presence of mutations in all three ras genes in human thyroid tumors Oncogene 5 1990 565 570
24. J.L. Meinkoth Biology of Ras in thyroid cells Cancer Treat Res 122 2004 131 148
25. V. Vasko, M. Ferrand, J. Di Cristofaro, P. Carayon, J.F. Henry, and C. de Micco Specific pattern of RAS oncogene mutations in follicular thyroid tumors J Clin Endocrinol Metab 88 2003 2745 2752
26. M. Orita, H. Iwahana, H. Kanazawa, K. Hayashi, and T. Sekiya Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms Proc Natl Acad Sci U S A 86 1989 2766 2770
27. T. Andjelkovic, M. Pesic, J. Bankovic, N. Tanic, I.D. Markovic, and S. Ruzdijic Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R) Cancer Biol Ther 7 2008 1024 1032
28. N. Shoman, S. Klassen, A. McFadden, M.G. Bickis, E. Torlakovic, and R. Chibbar Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen Mod Pathol 18 2005 250 259
29. F.J. Esteva, H. Guo, and S. Zhang PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer Am J Pathol 177 2010 1647 1656
30. S. Al-Haddad, Z. Zhang, and E. Leygue Psoriasin (S100A7) expression and invasive breast cancer Am J Pathol 155 1999 2057 2066
31. A. Handra-Luca, H. Bilal, J.C. Bertrand, and P. Fouret Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation Am J Pathol 163 2003 957 967
32. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
33. D. Carbone, I. Chiba, and T. Mitsudomi Polymorphism at codon 213 within the p53 gene Oncogene 6 1991 1691 1692
34. F. Basolo, F. Pisaturo, and L.E. Pollina N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression Thyroid 10 2000 19 23
35. M.P. Quinlan, and J. Settleman Isoform-specific ras functions in development and cancer Future Oncol 5 2009 105 116
36. I.C. Cirstea, K. Kutsche, and R. Dvorsky A restricted spectrum of NRAS mutations causes Noonan syndrome Nat Genet 42 2010 27 29
37. K.M. Haigis, K.R. Kendall, and Y. Wang Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon Nat Genet 40 2008 600 608
38. J.C. Wolfman, and A. Wolfman Endogenous c-N-Ras provides a steady-state anti-apoptotic signal J Biol Chem 275 2000 19315 19323
39. J.A. Fagin, K. Matsuo, A. Karmakar, D.L. Chen, S.H. Tang, and H.P. Koeffler High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas J Clin Invest 91 1993 179 184
40. R. Donghi, A. Longoni, S. Pilotti, P. Michieli, G. Della Porta, and M.A. Pierotti Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland J Clin Invest 91 1993 1753 1760
41. T. Ito, T. Seyama, and T. Mizuno Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland Cancer Res 52 1992 1369 1371
42. D. Salvatore, A. Celetti, and N. Fabien Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours Eur J Endocrinol 134 1996 177 183
43. R. Malaguarnera, V. Vella, R. Vigneri, and F. Frasca p53 family proteins in thyroid cancer Endocr Relat Cancer 14 2007 43 60
44. C. Rommel, B.A. Clarke, and S. Zimmermann Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt Science 286 1999 1738 1741
45. C.W. Menges, and D.J. McCance Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor Oncogene 27 2008 2934 2940
46. L.P. Swift, A. Rephaeli, A. Nudelman, D.R. Phillips, and S.M. Cutts Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death Cancer Res 66 2006 4863 4871
47. A.A. Ahmed, X. Wang, and Z. Lu Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel Cancer Res 71 2011 5806 5817
48. G. He, J. Kuang, A.R. Khokhar, and Z.H. Siddik The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog Gynecol Oncol 122 2011 402 409
49. C. Eng, A.M. Mauer, and G.F. Fleming Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors Ann Oncol 12 2001 1743 1747
50. M. Bezler, J.G. Hengstler, and A. Ullrich Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells Mol Oncol 6 2012 516 529
51. R. Xu, N. Sato, and K. Yanai Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells Anticancer Res 29 2009 261 270
52. C.D. Britten PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types Cancer Chemother Pharmacol 71 2013 1395 1409
53. H.A. Burris 3rd Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway Cancer Chemother Pharmacol 71 2013 829 842
54. A.I. Marcus, J. Zhou, and A. O'Brate The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase Cancer Res 65 2005 3883 3893
55. D.A. Altomare, L. Zhang, and J. Deng GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt Clin Cancer Res 16 2010 486 496
56. E. Zhang, C. Zhang, Y. Su, T. Cheng, and C. Shi Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy Drug Discov Today 16 2011 140 146
57. T. Huang, M. Karsy, J. Zhuge, M. Zhong, and D. Liu B-Raf and the inhibitors: from bench to bedside J Hematol Oncol 6 2013 30
58. T. Zhu, J. Gu, and K. Yu Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models J Med Chem 49 2006 1373 1378
59. J.J. Wallin, J. Guan, and W.W. Prior Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer Sci Transl Med 2 2010 48ra66
60. Y.Y. Zaytseva, J.D. Valentino, P. Gulhati, and B.M. Evers mTOR inhibitors in cancer therapy Cancer Lett 319 2012 1 7
61. A. Shafer, C. Zhou, P.A. Gehrig, J.F. Boggess, and V.L. Bae-Jump Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis Int J Cancer 126 2010 1144 1154